Clinical Trials Logo
  1. Home
  2. Biliary Tract Neoplasms
  3. NCT06037655

Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC — Modified  

Biliary Tract Neoplasms Clinical Trial

Official title:
Gemcitabine/Cisplatin Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable Biliary Tract Carcinoma, A Single-arm Study

Clinical Trial Summary

The purpose of this study is to assess the safety and efficacy of Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim in neoadjuvant treatment of potentially resectable Biliary Tract Neoplasms.

Clinical Trial Description

After being informed about the study and potential risks, patients giving written informed consent will undergo a 1-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be receive Gemcitabine/cisplatin combined with Adebrelimab and Mecapegfilgrastim three weeks a cycle, surgery was performed after 4 cycles. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06037655
Study type Interventional
Source The First Affiliated Hospital with Nanjing Medical University
Contact Xiangcheng Li
Phone 18951999088
Email drlixc@163.com
Status Not yet recruiting
Phase Phase 2
Start date September 25, 2023
Completion date December 31, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01950572 - Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Completed NCT03101566 - Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer Phase 2
Recruiting NCT05237193 - A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
Recruiting NCT04584008 - Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics N/A
Completed NCT00196105 - Malignant Obstruction ZILVER Against Routine Therapy (MOZART I) N/A
Completed NCT02558959 - Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer Phase 2
Completed NCT02829918 - Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers Phase 2
Completed NCT02784353 - Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy N/A
Recruiting NCT05429203 - Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope N/A
Recruiting NCT02255669 - Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction N/A
Completed NCT01731821 - Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy Phase 3
Completed NCT00422409 - Endoscopic Stenting of Gastrointestinal Cancer N/A
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT03063554 - EUS BD vs ERCP TP for Pancreatic Cancer N/A
Terminated NCT02615210 - Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures N/A
Completed NCT04595058 - LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent N/A
Recruiting NCT04856761 - A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
Recruiting NCT03427242 - Apatinib for Advanced Biliary Carcinoma Phase 2
Terminated NCT00359320 - A Randomized Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy N/A
Completed NCT00980889 - RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction Phase 4